Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant
Mateo Mejía Saldarriaga, Jingmei Hsu(Cancer Research Institute), Koen van Besien(University Hospitals of Cleveland), Adrienne A. Phillips(Palmetto Hematology Oncology), Alexandra Gomez-Arteaga(Cornell University), Tsiporah B. Shore(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Yassine Tahri(Université Libre de Bruxelles), Sangmin Lee(Janssen (United States)), Zhengming Chen(Cornell University), Sebastian Mayer(Mount Sinai Hospital), Danielle Guarneri(Palmetto Hematology Oncology), Michael Samuel(NewYork–Presbyterian Hospital), Gail J. Roboz(Cornell University)
Cited by 0
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k